Evidence map›Paper›PMID 40485482›Full record

ArticleJournal of comparative effectiveness research2025

Cost-per-remitter for esketamine nasal spray versus quetiapine for treatment-resistant depression.

Kristin Clemens, Amanda Teeple, Benoit Rive, Noam Kirson, Urvi Desai, Jason Doran, Diab Eid, Alice Qu, Hannah Bowrey, Kruti Joshi

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of comparative effectiveness research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kristin ClemensRight Solutions Mental Health, Gaithersburg, MD 20877, USA.
Amanda TeepleJohnson and Johnson Innovative Medicine, Titusville, NJ 08560, USA.
Benoit RiveJanssen EMEA, Paris, France.
Noam KirsonAnalysis Group, Inc. Boston, MA 02199, USA.ORCID 0000-0001-5200-6883
Urvi DesaiAnalysis Group, Inc. Boston, MA 02199, USA.ORCID 0000-0001-5196-7201
Jason DoranAnalysis Group, Inc. Boston, MA 02199, USA.ORCID 0000-0002-5501-9433
Diab EidAnalysis Group, Inc. Boston, MA 02199, USA.
Alice QuAnalysis Group, Inc. Boston, MA 02199, USA.
Hannah BowreyJohnson and Johnson Innovative Medicine, Titusville, NJ 08560, USA.
Kruti JoshiJohnson and Johnson Innovative Medicine, Titusville, NJ 08560, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antidepressive AgentsDepressive Disorder, Treatment-ResistantKetamineQuetiapine FumarateAdministration, OralAdultAntipsychotic AgentsCost-Benefit AnalysisDelayed-Action PreparationsDrug Therapy, CombinationFemaleHumansMaleMedicaidMiddle AgedNasal SpraysAntidepressive AgentsAntipsychotic AgentsDelayed-Action PreparationsEsketamineKetamineNasal SpraysQuetiapine Fumaratecost-benefitcost efficiencycost offsetcost-per-remittereconomic modelesketaminequetiapinetreatment-resistant depression

Identifiers

PMID40485482
PMCPMC12224085

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.